ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Dustin A. Deming et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Jonathan M. Loree et al.|Annals of Oncology|2018Cited by 239
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|The Lancet Oncology|2024Cited by 124
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Kanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|Journal of Clinical Oncology|2023Cited by 77